Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22587728 | 0.89 | BRD4 (0.57) | BRD4 | |
| SCHEMBL22588209 | 0.89 | BRD4 (0.72) | BRD4 | |
| SCHEMBL22588319 | 0.89 | BRD4 (0.56) | BRD4 | |
| SCHEMBL24397918 | 0.84 | BRD4 (0.58) | BRD4 | |
| SCHEMBL22588343 | 0.84 | BRD4 (0.64) | BRD4 | |
| SCHEMBL31589682 | 0.82 | BRD4 (0.70) | BRD4 | |
| SCHEMBL24397937 | 0.81 | BRD4 (0.57) | BRD4 | |
| SCHEMBL22588455 | 0.81 | BRD4 (0.55) | BRD4 | |
| SCHEMBL24398044 | 0.81 | BRD4 (0.55) | BRD4 | |
| SCHEMBL22588375 | 0.81 | BRD4 (0.61) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | Tay Therapeutics Limited (GB) | 2025-08-12 | — | — | US | disclosed |
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2022-06-30 | — | — | US | disclosed |
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2022-06-30 | — | — | US | disclosed |
| CN-113924298-A | Compounds comprising N-methyl-2-pyridone and pharmaceutically acceptable salts | 邓迪大学 | 2022-01-11 | — | — | CN | disclosed |
| WO-2020216779-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020216779-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | TPMT, IL5, P2RY6 | BRD4 303/4885 |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | TPMT, IL5, P2RY6 | BRD4 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.